How is Survodutide administered?
This describes how Survodutide is typically administered in clinical and research references, not a self-administration guide. The usual route is Subcutaneous, on a once weekly schedule, generally over open-ended, titrate over months. Specific dosing is individual and beyond general information, and human evidence for Survodutide is limited.
Administration at a glance (reference data)
- Route: Subcutaneous
- Schedule: Once weekly
- Cycle length: Open-ended, titrate over months
- Half-life: ~6 days
References
- Survodutide for treatment of obesity, Phase 2 trial — le Roux CW et al., Lancet Diabetes Endocrinol, 2024
- A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis — Sanyal et al., N Engl J Med, 2024
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Survodutide
Last updated 2026-06-15.